Allarity Therapeutics Files 8-K: Material Agreement

TL;DR

Allarity Therapeutics signed a big deal on 5/17, filing an 8-K with financials.

AI Summary

On May 17, 2024, Allarity Therapeutics, Inc. entered into a material definitive agreement, the details of which are not fully disclosed in this filing. The company also filed financial statements and exhibits related to this event. This filing is a current report under the Securities Exchange Act of 1934.

Why It Matters

This filing indicates a significant development for Allarity Therapeutics, potentially involving a new partnership, acquisition, or financing, which could impact its future operations and stock value.

Risk Assessment

Risk Level: medium — The filing indicates a material definitive agreement, which could represent significant opportunities or risks for the company, but the lack of specific details necessitates a medium risk assessment.

Key Players & Entities

• Allarity Therapeutics, Inc. (company) — Registrant
• May 17, 2024 (date) — Date of earliest event reported
• 001-41160 (other) — Commission File Number
• 24 School Street, 2nd Floor, Boston, MA 02108 (address) — Principal executive offices

FAQ

Key Financial Figures

• $0.0001 — ch registered Common Stock, par value $0.0001 per share ALLR The Nasdaq Stock Mar
• $30 million — terms of the Amendment was increased to $30 million. The foregoing descriptions of the Ame

Filing Documents

• ea0206584-8k_allarity.htm (8-K) — 31KB
• ea020658401ex10-1_allarity.htm (EX-10.1) — 7KB
• ea020658401ex99-1_allarity.htm (EX-99.1) — 13KB
• ex99-1_001.jpg (GRAPHIC) — 9KB
• 0001213900-24-045382.txt ( ) — 241KB
• allr-20240517.xsd (EX-101.SCH) — 3KB
• allr-20240517_lab.xml (EX-101.LAB) — 33KB
• allr-20240517_pre.xml (EX-101.PRE) — 22KB
• ea0206584-8k_allarity_htm.xml (XML) — 4KB

01 Entry into a Material Definitive Agreement

Item 1.01 Entry into a Material Definitive Agreement. As previously reported in our Current Report on Form 8-K filed with the Securities and Exchange Commission on March 20, 2024, on March 19, 2024, Allarity Therapeutics, Inc. (the "Company"), entered into an At-The-Market Issuance Sales Agreement (the "Agreement") with Ascendiant Capital Markets, LLC (the "Agent"), pursuant to which the Company may offer and sell, from time to time, through the Agent, shares (the "Placement Shares") of the Company's common stock. On May 17, 2024, the parties to the Agreement entered into a First Comprehensive Amendment to the Agreement (the "Amendment"). The amount of the Placement Shares that may be sold under and pursuant to the terms of the Amendment was increased to $30 million. The foregoing descriptions of the Amendment are qualified in their entirety by reference to the full text of such Amendment, a copy of which is attached hereto as Exhibits 10.1, and is incorporated herein in its entirety by reference.

01 Regulation FD Disclosure

Item 7.01 Regulation FD Disclosure. On May 20, 2024, the Company, issued a press release announcing that it had received formal written notice from The Nasdaq Stock Market, LLC, confirming that the Company has regained compliance with the minimum stockholders' equity requirement as set forth in Listing Rule 5550(b)(1). A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 10.1 First Comprehensive Amendment to At-The-Market Issuance Sales Agreement, dated May 17, 2024 99.1 Press Release, dated May 20, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) 1

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Allarity Therapeutics, Inc. By: /s/ Thomas H. Jensen Thomas H. Jensen Chief Executive Officer Dated: May 21, 2024 2

View Full Filing

View this 8-K filing on SEC EDGAR